Spacer Comparison In Adult Asthmatics
Spacers are used by people with respiratory diseases who have problems using MDIs (metered dose inhalers). This study used fluticasone propionate/salmeterol to look at the pharmacokinetic profiles produced by different spacers in their washed and un-washed states.
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||See Detailed Description|
- The pharmacokinetic profile of fluticasone propionate (in particular the area under the curve to time t and the maximum concentration)
- The pharmacokinetic profile of salmeterol and the time to maximum concentration of fluticasone propionate
|Study Start Date:||March 2005|
Drug: fluticasone propionate/salmeterol
A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE™/ADVAIR™ 250 HFA MDI without spacer and with AeroChamber-Max spacer and VOLUMATIC™ both in their washed and unwashed states in adult subjects with mild or intermittent asthma.